This will take effect February 24, 2014
Overview and Clinical Utility:
On February 24, 2014, PathGroup Labs will discontinue T-Uptake Testing. Historically, T-Uptake testing was used primarily in conjunction with Total T4 to calculate the Free Thyroxine Index (FTI), a surrogate measure of Free T4. T-Uptake is of little clinical value alone; it’s primary use was for determining the FTI. Free T4, or Thyroxine Free, is readily available in almost all clinical laboratories and is the preferred test alternative to T-Uptake and the Free Thyroxine Index. The American Thyroid Association recommends first line screening for thyroid disorders with a high sensitivity (3rd generation) TSH assay. TSH may be ordered with reflex to Free T4, if abnormal. Note that custom panels with T-Uptake included will be amended. T-Uptake and FTI will be removed where applicable.
Click Here to read more.